5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Fátima Cardoso(Université Paris Cité), Eric P. Winer(Dana-Farber Cancer Institute), Fabrice André(Inserm), Giuseppe Curigliano(European Institute of Oncology), Theresa Wiseman(Royal Marsden Hospital), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Mona Elzayat(Europa Donna), Belinda E. Kiely(National Health and Medical Research Council), S.-B. Kim(Ulsan College), A. Costa(European School of Oncology), NU Lin(Dana-Farber Cancer Institute), Silvia P. Neciosup(Instituto Nacional de Enfermedades Neoplásicas), D.A. Vorobiof, B.V. Offersen(Aarhus University Hospital), Rajneesh Kaur(National Stroke Association of Malaysia), Prudence A. Francis(Peter MacCallum Cancer Centre), Nadia Harbeck(Breast Center), Renate Haidinger, Matti Aapro(Breast Center), Maria João Cardoso(Champalimaud Foundation), Larry Norton(Memorial Sloan Kettering Cancer Center), Nagi S. El Saghir(American University of Beirut Medical Center), Bella Kaufman(Sheba Medical Center), Laura Biganzoli(Hospital of Prato), Javier Cortés(Villa Maria Hospital), Shinji Ohno(National Hospital Organization Kyushu Cancer Center), Elżbieta Senkus(Gdańsk Medical University), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Frédérique Penault‐Llorca(Institut Claudius Regaud), L.A. Carey(University of North Carolina Health Care), Karen A. Gelmon(BC Cancer Agency), Olivia Pagani(European University Cyprus), Jonas Bergh(Karolinska University Hospital), Joseph Gligorov(Sorbonne Université), Frances Boyle(Royal North Shore Hospital), Shirley Mertz(Metastatic Breast Cancer Network), Lesley Fallowfield(Brighton and Sussex Medical School), A. Prat(Target (United States)), Hope S. Rugo(University of California, San Francisco), Xin Hu(Fudan University Shanghai Cancer Center), G. W. Sledge(Stanford Medicine), C.H. Barrios, Shani Paluch–Shimon(Hebrew University of Jerusalem), G.S. Bhattacharyya(Fortis Hospital), Christoph Thomssen(University Hospital in Halle)
Cited by 1,352
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k